Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Our primary focus is on developing novel drugs that we hope will help treat patients with certain blood cancers or solid tumor malignancies.
Karyopharm Therapeutics is investigating the safety and efficacy of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib in treatment-naïve patients with myelofibrosis.